瑞舒伐他汀与阿托伐他汀治疗冠心病的临床疗效比较研究

Clinical effect comparison study of atorvastatin and rosuvastatin in treating coronary disease

目的比较瑞舒伐他汀与阿托伐他汀治疗冠心病的临床疗效。方法选取广安市人民医院2014年收治的冠心病患者88例,根据治疗药物的不同分为阿托伐他汀组(n=48)和瑞舒伐他汀组(n=40)。患者入院后均给予常规治疗,阿托伐他汀组患者给予阿托伐他汀钙胶囊治疗,瑞舒伐他汀组患者给予瑞舒伐他汀钙片治疗,两组患者均持续治疗8周。比较两组患者治疗后相关指标〔低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、三酰甘油(TG)、总胆固醇(TC)、超敏C反应蛋白(hs-CRP)、同型半胱氨酸(Hcy)〕及不良反应发生情况。结果瑞舒伐他汀组患者LDL-C、TG、TC、hs-CRP、Hcy低于阿托伐他汀组,HDL-C高于阿托伐他汀组(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论采用瑞舒伐他汀治疗冠心病的临床疗效优于阿托伐他汀,可更有效降低血脂指标及炎性反应,且安全性高。

Objective To compare the clinical effect of atorvastatin and rosuvastatin in treating coronary disease.Methods A total of 88 cases of coronary disease patients were selected in 2014 year in People＇s Hospital of Guang＇an,which were divided into atorvastatin group（ n = 48） and rosuvastatin group（ n = 40）. All patients were given conventional therapy,atorvastatin group was treated with atorvastatin,rosuvastatin group was treated with rosuvastatin,both groups were treated for 8weeks. The related indexes（ LDL-C,HDL-C,TG,TC,hs-CRP,Hcy） and the incidence of adverse reactions were compared between the two groups. Results The rosuvastatin group of LDL-C,TG,TC,hs-CRP,Hcy were lower than atorvastatin group,HDL-C was higher than atorvastatin group（ P 〈0. 05）. No statistically significant difference of the incidence of adverse reactions was found between the two groups（ P 〈0. 05）. Conclusion Rosuvastatin has a better clinical effect in treating coronary disease than atorvastatin,it can more effectively lower the blood lipid indexes and inflammatory reactions,and with high safety.